FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma
Tokuzo Arao, Kazuomi Ueshima, Kazuko Matsumoto, Tomoyuki Nagai, Hideharu Kimura, Satoru Hagiwara, Toshiharu Sakurai, Seiji Haji, Akishige Kanazawa, Hisashi Hidaka, Yukihiro Iso, Keiichi Kubota, Mitsuo Shimada, Tohru Utsunomiya, Masashi Hirooka, Yoichi Hiasa, Yoshikazu Toyoki, Kenichi Hakamada, Kohichiroh Yasui, Takashi Kumada, Hidenori Toyoda, Shuichi Sato, Hiroyuki Hisai, Teiji Kuzuya, Kaoru Tsuchiya, Namiki Izumi, Shigeki Arii, Kazuto Nishio, Masatoshi Kudo – 13 August 2012 – The response rate to sorafenib in hepatocellular carcinoma (HCC) is relatively low (0.7%‐3%), however, rapid and d